Octave Bioscience nabs $32m Series B

Octave Bioscience, a developer of a care management platform for multiple sclerosis and other neurodegenerative diseases, has closed $32 million in Series B financing.

To read this article, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to read this article and more for free.

Share this